These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15268633)

  • 1. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
    Buckheit RW
    Expert Opin Investig Drugs; 2004 Aug; 13(8):933-58. PubMed ID: 15268633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
    Zaccarelli M; Tozzi V; Perno CF; Antinori A
    Curr HIV Res; 2004 Jul; 2(3):283-92. PubMed ID: 15279592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impacts of HIV-1 resistance mutations associated with nucleoside reverse transcriptase inhibitors on viral fitness].
    Zhou Q; Liao LJ; Huang HJ
    Bing Du Xue Bao; 2012 May; 28(3):291-6. PubMed ID: 22764534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
    Maldonado JO; Mansky LM
    Viruses; 2018 Jul; 10(7):. PubMed ID: 30029500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
    Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational approaches to resistance: nucleoside analogues.
    Mayers D
    AIDS; 1996 Nov; 10 Suppl 1():S9-13. PubMed ID: 8970670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
    Pham HT; Mesplède T; Wainberg MA
    Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
    Balzarini J
    Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
    Turner D; Brenner B; Wainberg MA
    J Antimicrob Chemother; 2004 Jan; 53(1):53-7. PubMed ID: 14645322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of primary drug resistance among recently HIV-1 infected adults.
    Barbour JD; Hecht FM; Wrin T; Liegler TJ; Ramstead CA; Busch MP; Segal MR; Petropoulos CJ; Grant RM
    AIDS; 2004 Aug; 18(12):1683-9. PubMed ID: 15280779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
    Cong ME; Heneine W; García-Lerma JG
    J Virol; 2007 Mar; 81(6):3037-41. PubMed ID: 17192300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.